iSpecimen (ISPC)
NASDAQ:ISPC
Top Page
iSpecimen
(NASDAQ:ISPC)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.14
▼(-53.55% Downside)
Action:DowngradedDate:04/02/26
The score is held down primarily by severe financial deterioration (sharp revenue decline, margin collapse, and ongoing cash burn) and bearish technical signals (price below all key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend, while corporate events are mixed with governance-related quorum issues offsetting operational/financing positives.
Positive Factors
Digital marketplace upgrade (SalesStack)
Completing SalesStack Milestone 2 and launching a live, AI-assisted marketplace is a structural improvement to core platform capabilities. It should lower unit servicing costs, speed supplier onboarding, improve matching efficiency, and scale order processing—supporting more durable revenue generation if adoption rises.
Negative Factors
Large revenue and margin deterioration
A ~42% revenue drop and a collapse of gross margin to ~1% signal a severe structural hit to the business model's economics. Such a shift reduces operating leverage benefits, undermines pricing power or mix, and raises doubt about the platform’s ability to sustain historically healthy margins if underlying demand or supplier economics have permanently shifted.
Read all positive and negative factors
Positive Factors
Negative Factors
Digital marketplace upgrade (SalesStack)
Completing SalesStack Milestone 2 and launching a live, AI-assisted marketplace is a structural improvement to core platform capabilities. It should lower unit servicing costs, speed supplier onboarding, improve matching efficiency, and scale order processing—supporting more durable revenue generation if adoption rises.
Read all positive factors
iSpecimen (ISPC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.27M
Dividend YieldN/A
Average Volume (3M)8.88M
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue Growth-67.73%
EPS Growth58.35%
CountryUS
Employees24
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,662,250
10 Day Avg. Volume698,577
30 Day Avg. Volume8,882,166
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)0.62
P/FCF Ratio-0.28
Enterprise Value/Market Cap-1.36
Enterprise Value/Revenue-3.01
Enterprise Value/Gross Profit-240.82
Enterprise Value/Ebitda0.66
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
iSpecimen Business Overview & Revenue Model
Company Description
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology...
How the Company Makes Money
iSpecimen primarily makes money by facilitating transactions on its marketplace between biospecimen buyers (e.g., pharmaceutical/biotech companies, diagnostics developers, academic and clinical researchers, and other research organizations) and bi...
iSpecimen Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.93M | 9.29M | 9.93M | 10.40M | 11.14M |
| Gross Profit | 24.11K | 3.99M | 5.11M | 5.65M | 5.89M |
| EBITDA | -5.38M | -12.73M | -8.80M | -8.80M | -5.86M |
| Net Income | -10.49M | -12.50M | -11.10M | -10.25M | -8.96M |
Balance Sheet | |||||
| Total Assets | 9.53M | 9.35M | 15.82M | 24.62M | 35.72M |
| Cash, Cash Equivalents and Short-Term Investments | 6.88M | 1.88M | 5.01M | 15.31M | 27.74M |
| Total Debt | 268.80K | 312.17K | 196.24K | 185.85K | 3.42M |
| Total Liabilities | 6.44M | 6.04M | 6.08M | 4.31M | 5.93M |
| Stockholders Equity | 3.09M | 3.31M | 9.74M | 20.31M | 29.79M |
Cash Flow | |||||
| Free Cash Flow | -4.24M | -8.30M | -10.55M | -9.01M | -11.71M |
| Operating Cash Flow | -4.24M | -8.26M | -5.81M | -5.82M | -10.67M |
| Investing Cash Flow | -1.00M | 1.98M | -7.23M | -3.19M | -1.04M |
| Financing Cash Flow | 10.24M | 5.82M | 70.89K | -3.42M | 38.75M |
iSpecimen Technical Analysis
Negative
0.31
Price Trends
0.25
Negative
0.34
Negative
0.70
Negative
Market Momentum
-0.03
Negative
36.05
Neutral
12.19
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISPC, the sentiment is Negative. The current price of 0.31 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.25, and below the 200-day MA of 0.70, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 36.05 is Neutral, neither overbought nor oversold. The STOCH value of 12.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ISPC.
iSpecimen Risk Analysis
iSpecimen disclosed 72 risk factors in its most recent earnings report. iSpecimen reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
iSpecimen Peers Comparison
UnderperformOutperform
Sector (51)
ISPC
iSpecimen
0.14
-1.28
-89.86%
INBS
Intelligent Bio Solutions
2.68
-9.62
-78.21%
BGLC
BioNexus Gene Lab Corp
2.30
0.13
5.99%
BIAF
bioAffinity Technologies, Inc.
4.09
-14.68
-78.21%
iSpecimen Corporate Events
Business Operations and StrategyShareholder Meetings
iSpecimen Faces Ongoing Shareholder Quorum Challenges for Meeting
Negative
Mar 13, 2026
On December 31, 2025, iSpecimen Inc. convened its 2025 Annual Meeting of Stockholders but adjourned it due to a lack of quorum, a problem that recurred when the meeting was reconvened on January 23, 2026, February 13, 2026, and March 13, 2026. The...
Shareholder Meetings
iSpecimen Faces Ongoing Annual Meeting Quorum Challenges
Negative
Feb 18, 2026
On December 31, 2025, iSpecimen Inc. convened its 2025 Annual Meeting of Stockholders but adjourned it after failing to reach a quorum, preventing votes on the proposals outlined in its November 21, 2025 proxy materials. The meeting was reconvened...
Business Operations and StrategyProduct-Related Announcements
iSpecimen Advances Digital Marketplace with SalesStack Milestone
Positive
Feb 6, 2026
On February 6, 2026, iSpecimen announced it had successfully completed Milestone 2 of its SalesStack digital transformation program, delivering full system integration and activating a live production marketplace that links customer requests with ...
Shareholder Meetings
iSpecimen Reschedules 2025 Annual Meeting Amid Quorum Issues
Negative
Jan 27, 2026
iSpecimen Inc. convened its 2025 Annual Meeting of Stockholders on December 31, 2025, but the meeting was adjourned twice—first on December 31 and again when reconvened on January 23, 2026—because the company failed to achieve a quorum...
Shareholder Meetings
iSpecimen Postpones Annual Meeting Due to Lack Quorum
Neutral
Jan 5, 2026
On December 31, 2025, iSpecimen Inc. convened its 2025 annual meeting of stockholders but adjourned it after failing to achieve a quorum of shareholders needed to conduct business on the proposals previously circulated. The company plans to reconv...
Business Operations and StrategyPrivate Placements and Financing
iSpecimen Completes Private Placement, Engages IR Consulting Firm
Positive
Jan 5, 2026
On December 31, 2025, iSpecimen Inc. completed a private placement of its Series C Convertible Non-Voting Preferred Stock and entered into a Consulting Agreement with IR Agency LLC to provide marketing, advertising, and investor communications ser...
Private Placements and Financing
iSpecimen raises capital via new Series C preferred
Neutral
Jan 2, 2026
On December 30, 2025, iSpecimen Inc. entered into a Securities Purchase Agreement with accredited investors to issue 6,875 shares of newly created Series C Convertible Non-Voting Preferred Stock, each with a stated value of $1,000 and sold at $800...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.